Model for end-stage liver disease (MELD) and allocation of donor livers.

By R. Wiesner, E. Edwards, R. Freeman, A. Harper, R. Kim, P. Kamath, W. Kremers, J. Lake, T. Howard, R. Merion and 2 more. Gastroenterology, 2003

2,497 citations recorded by the source corpus.

Subfields: Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/82acecb7a041dfaa722dc6c995582b024266796e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Andrew K. Burroughs
2. X. Forns

In Surgery

1. R. Bellomo
2. John A. Kellum

Citations in the corpus

• Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. (2014, methodology): “Results From 2002-2012, there were 61,868 adult LT recipients in the U.S., including 10,061 HCC patients that received LT.”
• EASL Clinical Practice Guidelines: Liver transplantation. (2016, methodology): “The Child-Pugh-Turcotte classification and since 2002 also the model of end-stage liver disease (MELD) score (based on objective measures such as creatinine, bilirubin and international normalized ratio) are used for patient priority [9].”
• The Survival Benefit of Liver Transplantation (2005, background): “It is established that MELD is an important predictor of waiting list mortality (11,17,18), and several authors have recently reported that MELD is predictive of post-transplant mortality risk (6,19).”
• Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group (2012, background): “The prognostic impact of renal function in liver disease is reflected by the inclusion of SCr in the Model for End-Stage Liver Disease (MELD) score, which is used to prioritize patients for liver transplantation [9].”
• Pharmacokinetics and dosage adjustment in patients with renal dysfunction (2008, background): “Another classification scheme, the model for end-stage liver disease (MELD), is based on serum bilirubin concentration, serum creatinine, the international normalized ratio (INR) of prothrombin time, and the underlying cause of liver disease [ 106 ].”